Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Vyepti by H. Lundbeck A/S shows robust Phase IV efficacy in chronic migraine with medication-overuse headache patients H. Lundbeck A/S reports rapid and significant migraine prevention benefits for Vyepti® (eptinezumab) in Phase IV RESOLUTION trial, targeting MOH patients. byPallavi MadhirajuJune 21, 2025